September 24, 2026 DPP-4 inhibitors may have specific autoimmune risks Associations with dermatomyositis, bullous pemphigoid, psoriasis, and autoimmune thyroiditis differed across commonly used diabetes drug classes. MDSpire News
September 02, 2026 What heat brings to acute care Researchers screened more than 1,800 diagnosis categories across nearly 917,000 acute-care encounters in Chicago. MDSpire News
August 31, 2026 Emergency diagnosis may flag poor outcomes beyond cancer Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality. MDSpire News
August 20, 2026 Musings from The Power List: Daniel Vitt From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development The Medicine Maker
July 13, 2026 In Vivo CAR T: A New Route to Treating Autoimmune Disease How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments The Medicine Maker
July 09, 2026 Top 10 Evidence-Based Essentials in Neurology A structured framework of guidelines, trials, therapies, and tools used in clinical practice. MDSpire News
July 07, 2026 Head-to-Head Trial in Relapsing MS The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity. MDSpire News
June 29, 2026 Side Effects: The Gut Goes Rogue When fiber metabolism falters in lupus, the microbiome may start dining on the host instead. This week: mucin-munching bugs, brain-delivered DHA with no cognitive payoff, and lipid-loaded MS lesions that may not be innocent bystanders. MDSpire News
June 17, 2026 Oculomics: Beyond the Buzzword Joseph J. Pizzimenti, OD, FAAO, FORS, discusses the capabilities of oculomics in retina and neuro-ophthalmology, Optometric Management
June 15, 2026 FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight. MDSpire News